Enteris Biopharma

Enteris works with pharmaceutical partners to improve the solubility of hard-to-dose therapeutics.  The company’s core Peptelligence drug delivery technology allows for oral delivery of peptides and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to become more operationally oriented, actively building a wholly-owned portfolio of milestones and royalties throughout-licensing activities.